Philip Agop Philip

Summary

Affiliation: Wayne State University
Country: USA

Publications

  1. ncbi Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer
    Philip A Philip
    Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    Cancer 118:2424-30. 2012
  2. ncbi Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment
    Philip A Philip
    Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    J Clin Oncol 27:5660-9. 2009
  3. ncbi Targeting angiogenesis in pancreatic cancer
    Philip A Philip
    Karmanos Cancer Center, Detroit, MI 48201, USA
    Lancet 371:2062-4. 2008
  4. ncbi Experience with docetaxel in the treatment of gastric cancer
    Philip A Philip
    The Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Semin Oncol 32:S24-38. 2005
  5. ncbi Novel targets for pancreatic cancer therapy
    Philip A Philip
    Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R Street, 4 HWCRC, Detroit, MI 48201, USA
    Surg Oncol Clin N Am 19:419-29. 2010
  6. ncbi Phase II study of erlotinib in patients with advanced biliary cancer
    Philip A Philip
    Karmanos Cancer Institute, Wayne State University, 4 HWCRC, 4100 John R St, Detroit, MI 48201, USA
    J Clin Oncol 24:3069-74. 2006
  7. ncbi Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer
    Philip A Philip
    Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    J Clin Oncol 23:6657-63. 2005
  8. ncbi A review of systemic therapy for advanced pancreatic cancer
    Basil F El-Rayes
    Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI 48201, USA
    Clin Adv Hematol Oncol 1:430-4. 2003
  9. ncbi Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205
    Philip A Philip
    Wayne State University, Karmanos Cancer Institute, GI Oncology, Detroit, MI 48201, USA
    J Clin Oncol 28:3605-10. 2010
  10. ncbi Gemcitabine and platinum combinations in pancreatic cancer
    Philip Agop Philip
    Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Cancer 95:908-11. 2002

Collaborators

Detail Information

Publications59

  1. ncbi Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer
    Philip A Philip
    Karmanos Cancer Institute, Detroit, Michigan 48201, USA
    Cancer 118:2424-30. 2012
    ..Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) are rational targets for therapy in hepatocellular cancer (HCC)...
  2. ncbi Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment
    Philip A Philip
    Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    J Clin Oncol 27:5660-9. 2009
    ..Patients with either metastatic or locally advanced PDAC must be studied separately...
  3. ncbi Targeting angiogenesis in pancreatic cancer
    Philip A Philip
    Karmanos Cancer Center, Detroit, MI 48201, USA
    Lancet 371:2062-4. 2008
  4. ncbi Experience with docetaxel in the treatment of gastric cancer
    Philip A Philip
    The Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Semin Oncol 32:S24-38. 2005
    ..This review provides an overview of these studies and suggestions for future directions in the treatment of gastric cancer...
  5. ncbi Novel targets for pancreatic cancer therapy
    Philip A Philip
    Division of Hematology and Oncology, Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R Street, 4 HWCRC, Detroit, MI 48201, USA
    Surg Oncol Clin N Am 19:419-29. 2010
    ..This article discusses various possible new targets and new agents for the anticancer therapy for PDA...
  6. ncbi Phase II study of erlotinib in patients with advanced biliary cancer
    Philip A Philip
    Karmanos Cancer Institute, Wayne State University, 4 HWCRC, 4100 John R St, Detroit, MI 48201, USA
    J Clin Oncol 24:3069-74. 2006
    ..The primary objective of this study was to determine the proportion of patients with advanced BILI who were progression-free at 6 months...
  7. ncbi Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer
    Philip A Philip
    Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    J Clin Oncol 23:6657-63. 2005
    ..Erlotinib (Tarceva, OSI-774; OSI Pharmaceuticals, Melville, NY) is a receptor tyrosine kinase inhibitor with specificity for the EGFR/HER1...
  8. ncbi A review of systemic therapy for advanced pancreatic cancer
    Basil F El-Rayes
    Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI 48201, USA
    Clin Adv Hematol Oncol 1:430-4. 2003
    ..Future treatment regimens for pancreatic cancer will probably incorporate conventional cytotoxic drugs and novel targeted agents...
  9. ncbi Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205
    Philip A Philip
    Wayne State University, Karmanos Cancer Institute, GI Oncology, Detroit, MI 48201, USA
    J Clin Oncol 28:3605-10. 2010
    ..This trial was conducted to evaluate the contribution of an EGFR-targeted agent to standard gemcitabine therapy. Cetuximab is a monoclonal antibody against the ligand-binding domain of the receptor...
  10. ncbi Gemcitabine and platinum combinations in pancreatic cancer
    Philip Agop Philip
    Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Cancer 95:908-11. 2002
    ..Pilot Phase II studies combining gemcitabine with cisplatin have shown improved outcomes in objective response rates and survival; however, these findings must be confirmed in larger randomized studies...
  11. ncbi Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma
    P A Philip
    Department of Internal Medicine, Division of Hematology and Oncology, Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA
    Cancer 92:569-77. 2001
    ..A Phase II study was undertaken to determine the efficacy of gemcitabine in combination with cisplatin in patients with locally advanced and metastatic pancreatic carcinoma based on these considerations...
  12. ncbi Biochemotherapy for melanoma
    P A Philip
    Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, 3990 John R Street, 501 Hudson Building, Detroit, MI 48201, USA
    Curr Oncol Rep 2:314-21. 2000
    ..At this time, biochemotherapy is under evaluation in a well-designed prospective, randomized trial to identify whether there is benefit to this strategy, compared with chemotherapy alone...
  13. ncbi Concurrent inhibition of NF-kappaB, cyclooxygenase-2, and epidermal growth factor receptor leads to greater anti-tumor activity in pancreatic cancer
    Shadan Ali
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    J Cell Biochem 110:171-81. 2010
    ..Based on our preclinical in vitro and in vivo results, we conclude that this multi-targeted combination could be developed for the treatment of PC patients whose tumors express high levels of COX-2, EGFR, and NF-kappaB...
  14. ncbi Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells
    Yiwei Li
    Department of Pathology and Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Cancer Res 65:6934-42. 2005
    ..Theses results warrant carefully designed clinical studies investigating the combination of soy isoflavones and commonly used chemotherapeutic agents for the treatment of human cancers...
  15. ncbi Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer
    Shadan Ali
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
    Mol Cancer Ther 7:1708-19. 2008
    ..These results suggest that the utilization of B-DIM could be a useful strategy for achieving better treatment outcome in patients with activated status of EGFR and NF-kappaB in their tumors...
  16. ncbi Systemic therapy for advanced pancreatic cancer
    Basil F El-Rayes
    Division of Haematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Expert Rev Anticancer Ther 2:426-36. 2002
    ..Ongoing and future treatment regimens for pancreatic cancer will incorporate traditional cytotoxic drugs and novel targeted therapies...
  17. ncbi Apoptosis-inducing effect of chemotherapeutic agents is potentiated by soy isoflavone genistein, a natural inhibitor of NF-kappaB in BxPC-3 pancreatic cancer cell line
    Yiwei Li
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Pancreas 28:e90-5. 2004
    ....
  18. ncbi Potentiation of the effect of erlotinib by genistein in pancreatic cancer: the role of Akt and nuclear factor-kappaB
    Basil F El-Rayes
    Division of Hematology/Oncology, Department of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Cancer Res 66:10553-9. 2006
    ..Akt and NF-kappaB inhibition represents one of the mechanisms for the potentiation of erlotinib- and gemcitabine-induced cell death by genistein...
  19. ncbi Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study
    Sana Al-Sukhun
    Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan, USA
    Am J Clin Oncol 26:543-9. 2003
    ..4, 24.3 and 40 months. The treatment program was active, but only moderately well tolerated. Modification of this regimen with newer, less toxic drugs may provide better results and reduced toxicity...
  20. ncbi Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer
    Sanjeev Banerjee
    Department of Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Pharm Res 27:1146-58. 2010
    ..However, the concentration of TQ required was considered to be high to show this efficacy. Therefore, novel analogs of TQ with lower IC(50) are highly desirable...
  21. ncbi miR-146a suppresses invasion of pancreatic cancer cells
    Yiwei Li
    Departments of Pathology and Internal Medicine, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Cancer Res 70:1486-95. 2010
    ..Our findings reveal DIM and isoflavone as nontoxic activators of a miRNA that can block pancreatic cancer cell invasion and metastasis, offering starting points to design novel anticancer agents...
  22. ncbi Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines
    Basil F El-Rayes
    Department of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, Detroit, MI 48201, USA
    Mol Cancer Ther 3:1421-6. 2004
    ....
  23. ncbi Phase II trial of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site
    Bryan J Schneider
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 0848, USA
    Cancer 110:770-5. 2007
    ..The purposes of this study were to evaluate efficacy and toxicity of the combination of carboplatin, gemcitabine, and capecitabine in patients with carcinoma of unknown primary site (CUP)...
  24. ncbi Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy
    Shadan Ali
    Department of Hematology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Mol Cancer Ther 4:1943-51. 2005
    ....
  25. ncbi A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancer
    Lata Chandi Thatai
    Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Am J Clin Oncol 29:484-9. 2006
    ..CONCLUSIONS: Triple cytotoxic therapy based on concurrent doxorubicin and docetaxel with infusional 5-flourouracil (5-FU) does not appear to significantly improve the pathologic response in patients with locally advanced breast cancer...
  26. ncbi Gemcitabine sensitivity can be induced in pancreatic cancer cells through modulation of miR-200 and miR-21 expression by curcumin or its analogue CDF
    Shadan Ali
    Division of Hematology Oncology, Department of Pathology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Cancer Res 70:3606-17. 2010
    ..These results prompt further interest in CDF as a drug modality to improve treatment outcome of patients diagnosed with PC as a result of its greater bioavailability in pancreatic tissue...
  27. ncbi Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy
    Asfar S Azmi
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Curr Cancer Drug Targets 10:319-31. 2010
    ..No tumor inhibition was found in mut-p53 BxPC-3 xenografts. In light of our results, the inhibitors of MDM2 warrant clinical investigation as new agents for PC treatment...
  28. ncbi Protein kinase C: a target for therapy in pancreatic cancer
    Bassel F El-Rayes
    Department of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
    Pancreas 36:346-52. 2008
    ..This study investigated the expression of PKC in pancreatic tumor tissue in comparison to adjacent normal tissue and determined the modulation of PKC by bryostatin-1 (BRYO) on pancreatic cancer cell lines...
  29. ncbi Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer
    Edgar Ben-Josef
    Department of Radiation Oncology, Wayne State University and the Karmanos Cancer Institute, Detroit, MI, USA
    Int J Radiat Oncol Biol Phys 59:454-9. 2004
    ..To overcome some of these restrictions, we have developed a regimen of intensity-modulated radiotherapy (IMRT) with concurrent capecitabine...
  30. ncbi Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer
    Sanjeev Banerjee
    Department of Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Cancer Res 65:9064-72. 2005
    ....
  31. ncbi Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer
    Shirish M Gadgeel
    Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute and Wayne State University, Detroit, MI 48201, USA
    Am J Clin Oncol 26:37-41. 2003
    ..This regimen needs to be further evaluated in combination with other agents and as a component of multimodality therapy in gastric cancer...
  32. ncbi Clinicopathological analysis of primary epithelial appendiceal neoplasms
    Sachin Gupta
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University, 4100 John R, Detroit, MI 48201, USA
    Med Oncol 27:1073-8. 2010
    ..Three distinct histopathological disease entities exist in appendiceal tumors. The prognosis and management of these tumors should be based on the extent of disease and pathologic diagnosis...
  33. ncbi Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center
    Michael S Simon
    Hudson Webber Cancer Research Building, 4th Floor, 4100 John R St, Detroit, MI 48201, USA
    J Clin Oncol 22:2046-52. 2004
    ..The practice patterns of medical oncologists at a large National Cancer Institute Comprehensive Cancer Center in Detroit, MI were evaluated to better understand factors associated with accrual to breast cancer clinical trials...
  34. ncbi Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines
    Shirish M Gadgeel
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
    Cancer 115:2165-76. 2009
    ..The authors hypothesized that genistein, through the inhibition of NF-kappaB, could enhance the activity of EGFR-TKIs in NSCLCs...
  35. ncbi PAR-4 as a possible new target for pancreatic cancer therapy
    Asfar S Azmi
    Department of Pathology, Wayne State University School of Medicine, Detroit, MI 48201, USA
    Expert Opin Ther Targets 14:611-20. 2010
    ..PC is an oncogenic kras driven disease, which is known to downregulate Par-4. Therefore, this review highlights its significance and builds a strong case supporting the role of Par-4 as a possible therapeutic target in PC...
  36. ncbi CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy
    Nazik Hammad
    Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
    Asia Pac J Clin Oncol 6:98-105. 2010
    ....
  37. ncbi Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor
    Shirish M Gadgeel
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Cancer 110:2775-84. 2007
    ..Therefore, it was hypothesized that tumor EGFR mutation status may influence the effectiveness of simultaneous EGFR and COX-2 inhibition in patients with NSCLC...
  38. ncbi Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells
    K M Wahidur Rahman
    Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, 715 HWCRC, 4100 John R, Detroit, MI 48201, USA
    Mol Cancer Ther 6:2757-65. 2007
    ..The data obtained from our studies could be a novel breakthrough in cancer therapeutics by using nontoxic agents, such as B-DIM, in combination with other conventional therapeutic agents, such as Taxotere...
  39. ncbi A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary
    Basil F El-Rayes
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Am J Clin Oncol 28:152-6. 2005
    ..This study was conducted to evaluate the efficacy and toxicity of combination carboplatin and paclitaxel in patients with adenocarcinoma of unknown primary site (ACUP)...
  40. ncbi Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells
    Shadan Ali
    Department of Internal Medicine, Wayne State University Detroit, MI, USA
    Breast Cancer Res Treat 90:25-31. 2005
    ..These results provide rationale for pre-clinical evaluation of this treatment strategy using animal models and in the design of clinical trials of this drug in combination with cytotoxic therapy...
  41. ncbi Phase I study of bryostatin 1 and gemcitabine
    Basil F El-Rayes
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 12:7059-62. 2006
    ..Bryostatin 1 enhanced the activity of antitumor agents including gemcitabine in preclinical models. The primary objective of this phase I study was to determine the recommended doses for phase II trials of bryostatin 1 and gemcitabine...
  42. ncbi A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin
    Basil F El-Rayes
    Division of Hematology and Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Am J Clin Oncol 30:101-5. 2007
    ..The primary objective of this study was to determine the maximum tolerated dose of UFT/leucovorin and gemcitabine...
  43. ncbi Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer
    Bassel F El-Rayes
    Karmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI 48201, USA
    Cancer Chemother Pharmacol 61:283-9. 2008
    ..A Phase-II study was undertaken to determine the activity of a dose attenuated schedule of irinotecan, capecitabine, and the COX-2 inhibitor celecoxib in patients with advanced colorectal cancer...
  44. ncbi Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors
    Basil F El-Rayes
    Division of Hematology/Oncology, Wayne State University, Karmanos Cancer Institute, Detroit, MI 48201, USA
    Invest New Drugs 23:57-62. 2005
    ..Major toxicities of the combination include the hand-foot syndrome, stomatitis and neutropenia...
  45. ncbi A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer
    Basil F El-Rayes
    Karmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI, 48201, USA
    Invest New Drugs 23:583-90. 2005
    ..A Phase II study was undertaken to determine the effect of gemcitabine by fixed-dose rate infusion (FDR), cisplatin and the COX-2 inhibitor, celecoxib, on the 6-month survival rate in patients with metastatic pancreatic cancer...
  46. ncbi Clinicopathologic analysis of pancreatic adenocarcinoma in African Americans and Caucasians
    Nat L Pernick
    Department of Pathology, Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, Detroit, USA
    Pancreas 26:28-32. 2003
    ..At the molecular level, African Americans had more frequent K- mutations to valine than did Caucasians...
  47. ncbi MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function
    Asfar S Azmi
    Department of Pathology, Karmanos Cancer Institute, Wayne State University, School of Medicine, Detroit, MI, United States
    Eur J Cancer 46:1122-31. 2010
    ..In conclusion, this study highlights a new role of MDM2 inhibitors in combination with cisplatin, and thus warrants further clinical investigation in human pancreatic tumours containing both wt-p53 and mut-p53...
  48. ncbi Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1
    Shadan Ali
    Barbara Ann Karmanos Cancer Institute, Wayne State University, 501 Hudson Building, 3990 John R Street, Detroit, MI 48201, USA
    Cancer Chemother Pharmacol 52:235-46. 2003
    ..Further investigation of the role of specific isoforms of PKC in the downstream molecular events of gemcitabine-induced cytotoxicity is warranted...
  49. ncbi MDM2 inhibitors for pancreatic cancer therapy
    Asfar S Azmi
    Hematology and Oncology, Internal Medicine, Wayne State University School of Medicine, Karmanos Cancer Institute, 732 HWCRC, 4100 John R Street, Detroit, MI 48201, USA
    Mini Rev Med Chem 10:518-26. 2010
    ..This review summarizes recent advancements in the development of MDM2 inhibitors, their novel primary and secondary targets and highlights their potential as therapeutics for PaCa...
  50. ncbi A phase I study of flavopiridol and docetaxel
    Basil F El-Rayes
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Invest New Drugs 24:305-10. 2006
    ..CONCLUSIONS: Neutropenia complicated by infection was the major dose-limiting toxicity. The recommended doses of flavopiridol and docetaxel for phase II trials are 50 and 60 mg/m2 every three weeks, respectively...
  51. ncbi Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells
    Yiwei Li
    Department of Pathology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    Cancer Res 69:6704-12. 2009
    ....
  52. ncbi Cytochrome p450 and glutathione transferase expression in squamous cell cancer
    Shadan Ali
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, USA
    Clin Cancer Res 10:4412-6. 2004
    ..CONCLUSION: Evaluation of CYP expression in the target tissue of interest is feasible. The clinical significance of CYPs and GST-pi alterations in the risk of developing SCCHN will need to be investigated in larger trials...
  53. ncbi Male fertility preservation and cancer treatment
    Elizabeth Puscheck
    Division of Reproductive Endocrine and Infertility, Department of Obstetrics and Gynecology, Wayne State University Medical School, Detroit, MI, USA
    Cancer Treat Rev 30:173-80. 2004
    ..The emphasis for future cancer treatment and its research regarding male fertility preservation needs further attention...
  54. ncbi Breast cancer in women with human immunodeficiency virus infection: implications for diagnosis and therapy
    Basil F El-Rayes
    Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA
    Breast Cancer Res Treat 76:111-6. 2002
    ..In general, the outcome of breast cancer in our small series of patients was worse than in a non-HIV population. HIV infection may influence the natural history and treatment of breast cancer...
  55. ncbi Protein kinases C isozymes are differentially expressed in human breast carcinomas
    Shadan Ali
    Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, United States
    Life Sci 84:766-71. 2009
    ....
  56. ncbi Histopathologic evidence of tumor regression in the axillary lymph nodes of patients treated with preoperative chemotherapy correlates with breast cancer outcome
    Lisa A Newman
    Department of Surgery, Karmanos Cancer Institute and Wayne State University, Detroit, Michigan 48109, USA
    Ann Surg Oncol 10:734-9. 2003
    ..However, the pathologic evaluation and prognostic significance of response in preoperatively treated lymph nodes have not been defined...
  57. ncbi Direct comparison of microarray gene expression profiles between non-amplification and a modified cDNA amplification procedure applicable for needle biopsy tissues
    Yiwei Li
    Department of Pathology, Karmanos Cancer Institute, 715 Hudson Webber Cancer Research Center, Wayne State University School of Medicine, 110 E Warren, 48201, Detroit, MI, USA
    Cancer Detect Prev 27:405-11. 2003
    ..These results suggest that the global gene expression profiles of small biopsy samples can be achieved by our modified method to facilitate the analysis of gene expression profiles for clinical application...
  58. ncbi Exploitation of protein kinase C: a useful target for cancer therapy
    Ashhar S Ali
    Department of Pathology, Karmanos Cancer Institute, Wayne State University, 4100 John R Street, Detroit, MI 48201, USA
    Cancer Treat Rev 35:1-8. 2009
    ..In conclusion, PKC remains a promising target for cancer prevention and therapy...
  59. ncbi Cytochrome p450 and glutathione transferase expression in human breast cancer
    Basil F El-Rayes
    Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
    Clin Cancer Res 9:1705-9. 2003
    ..The purpose of this study was to compare the expression of GST-Pi and CYPs 1A1, 2B6, 2E1, and 3A4 in paired samples of normal and malignant breast tissue from patients with breast cancer and women undergoing reduction mammoplasty...